Baidu
map

JAGS:化疗并不能延长老年乳腺癌患者生存期

2015-08-16 MedSci MedSci原创

为了探究化疗疗法的效果,研究人员分别对乳腺癌患者组和结肠癌患者组的患者进行化疗,研究表明:除非进行特殊的联合治疗,否则化疗很可能不会延长80岁以上的乳腺癌患者的寿命;然而,对于结肠癌患者,化疗疗法对89岁以下的老人都有效。德克萨斯大学健康科学中心的研究人员进行了这项研究,并将它发表在《美国老年病学学会杂志》上。研究人员使用了1992-2009年流行病监督及最终结果资料库(SEER)的相关数据,他们

为了探究化疗疗法的效果,研究人员分别对乳腺癌患者组和结肠癌组的患者进行化疗,研究表明:除非进行特殊的联合治疗,否则化疗很可能不会延长80岁以上的乳腺癌患者的寿命;然而,对于结肠癌患者,化疗疗法对89岁以下的老人都有效。德克萨斯大学健康科学中心的研究人员进行了这项研究,并将它发表在《美国老年病学学会杂志》上。

研究人员使用了1992-2009年流行病监督及最终结果资料库(SEER)的相关数据,他们收集的数据来自于14440位诊断为I期到IIIA期的雌激素受体阴性乳腺癌患者和26893位III期结肠癌患者,所有患者的年龄都超过65岁。

研究表明,对于乳腺癌患者,对65-69岁、70-74岁、75-79岁三个年龄段的患者使用化疗方案后死亡风险分别降低30%、26%、24%。但对80岁以上的女性,化疗并不能显著降低死亡风险。但有一个例外:对小部分年龄超过80岁的乳腺癌患者采用AC联合化疗方案(多柔比星和环磷酰胺)后,患者死亡风险减少29%。

在为乳腺癌患者选择治疗方案的时候,医生要考虑到许多因素,包括病人的年龄和健康状况、肿瘤的类型及特点(如分期、雌激素受体是否为阴性、HER2因子、淋巴结的状态等)。

与乳腺癌患者的结果相反,研究人员发现:在结肠癌患者中,对65岁以上的患者采用化疗方案是有效的。例如,对于80-85岁的结肠癌患者采用化疗后,死亡风险会降低21%。

研究人员认为,鉴于研究的样本量十分庞大,因此研究结果是十分可信的,因此,他们建议,由于老人的身体十分虚弱,而且对肿瘤细胞对化疗不敏感,化疗药对老人有不同程度的损害,不要对70岁以上的乳腺癌患者实施化疗。

原始出处:

Xianglin L. Du et al.Chemo unlikely to prolong survival in older breast cancer patients. Journal of American Geriatrics Society.22 July 201

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1741307, encodeId=a5071e41307af, content=<a href='/topic/show?id=755321140e' target=_blank style='color:#2F92EE;'>#AGS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2114, encryptionId=755321140e, topicName=AGS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9034929696, createdName=12498f17m77暂无昵称, createdTime=Mon Jan 18 08:31:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932528, encodeId=c78a1932528e0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri May 13 22:31:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378082, encodeId=55ee13e808215, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570966, encodeId=4c8815e09665f, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35728, encodeId=e4b035e2844, content=70岁以上乳腺癌就不化疗了, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Mon Aug 17 12:18:00 CST 2015, time=2015-08-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1741307, encodeId=a5071e41307af, content=<a href='/topic/show?id=755321140e' target=_blank style='color:#2F92EE;'>#AGS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2114, encryptionId=755321140e, topicName=AGS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9034929696, createdName=12498f17m77暂无昵称, createdTime=Mon Jan 18 08:31:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932528, encodeId=c78a1932528e0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri May 13 22:31:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378082, encodeId=55ee13e808215, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570966, encodeId=4c8815e09665f, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35728, encodeId=e4b035e2844, content=70岁以上乳腺癌就不化疗了, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Mon Aug 17 12:18:00 CST 2015, time=2015-08-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1741307, encodeId=a5071e41307af, content=<a href='/topic/show?id=755321140e' target=_blank style='color:#2F92EE;'>#AGS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2114, encryptionId=755321140e, topicName=AGS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9034929696, createdName=12498f17m77暂无昵称, createdTime=Mon Jan 18 08:31:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932528, encodeId=c78a1932528e0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri May 13 22:31:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378082, encodeId=55ee13e808215, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570966, encodeId=4c8815e09665f, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35728, encodeId=e4b035e2844, content=70岁以上乳腺癌就不化疗了, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Mon Aug 17 12:18:00 CST 2015, time=2015-08-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1741307, encodeId=a5071e41307af, content=<a href='/topic/show?id=755321140e' target=_blank style='color:#2F92EE;'>#AGS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2114, encryptionId=755321140e, topicName=AGS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9034929696, createdName=12498f17m77暂无昵称, createdTime=Mon Jan 18 08:31:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932528, encodeId=c78a1932528e0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri May 13 22:31:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378082, encodeId=55ee13e808215, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570966, encodeId=4c8815e09665f, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35728, encodeId=e4b035e2844, content=70岁以上乳腺癌就不化疗了, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Mon Aug 17 12:18:00 CST 2015, time=2015-08-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1741307, encodeId=a5071e41307af, content=<a href='/topic/show?id=755321140e' target=_blank style='color:#2F92EE;'>#AGS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2114, encryptionId=755321140e, topicName=AGS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9034929696, createdName=12498f17m77暂无昵称, createdTime=Mon Jan 18 08:31:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932528, encodeId=c78a1932528e0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri May 13 22:31:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378082, encodeId=55ee13e808215, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570966, encodeId=4c8815e09665f, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Aug 18 05:31:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35728, encodeId=e4b035e2844, content=70岁以上乳腺癌就不化疗了, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Mon Aug 17 12:18:00 CST 2015, time=2015-08-17, status=1, ipAttribution=)]
    2015-08-17 stupidox

    70岁以上乳腺癌就不化疗了

    0

相关资讯

JAMA Oncol:为预防乳腺癌,女性保持体重很重要!

    超过三分之二的美国女性超重或肥胖,这增加了她们绝经后患乳腺癌的风险。在女性健康倡议(WHI)临床试验延长随访后,这个二次分析调查了超重和肥胖与绝经后浸润性乳腺癌的风险的关联。    WHI的临床试验方案引入测量身高,体重,基线,一年或二年的乳房X光检查,并判定乳腺癌终点,该研究共包括了美国40个临床中心的67142例50岁至79岁的绝经后女性。这些女

Scientific Reports:乳腺癌和前列腺癌治疗的新希望——新的生物标志物的发现

Cedars-Sinai的研究人员发现了一种新的可在许多乳腺癌和前列腺癌发展过程中起作用的遗传标志物。这一发现将有助于临床医生更好的识别对侵袭性癌症的化疗药物有反应的患者。该研究结果发表于《科学报告》杂志中。“理解和识别生物学标志物是癌症研究和护理过程中中至关重要的一步,”该研究第一作者,Cedars-Sinai外科病研究副主席Michael Freeman博士说道,“以这项研究为例的新的分析策略

Oncogene:昆明动物所揭示KLF5转录因子在乳腺癌中的功能和机制

转移是导致乳腺癌患者死亡的主要原因,因此防治转移是乳腺癌研究的关键。而在乳腺癌中,基底型ER/PR/HER2三阴性乳腺癌恶性程度最高,具有较高的侵袭性,术后复发转移风险高,疾病进展快,目前还没有找到有效的药物治疗靶标,是乳腺癌治疗的瓶颈和研究的热点。中国科学院昆明动物研究所研究员陈策实领导的肿瘤生物学实验室通过多年研究证实KLF5在三阴性乳腺癌中高表达,是三阴性乳腺癌一个潜在治疗靶点。然而,KLF

Breast Cancer Res:乳腺癌新型生物标志物及治疗靶点

一篇发表于国际杂志Breast Cancer Research上的研究报告中,来自波士顿大学医学院的研究者开发出了一种新型方法,其或许可以帮助检测/治疗恶性乳腺癌。 基底细胞样型乳腺癌 (Basal-like breast cancer,BLBC)是一种恶性乳腺癌,其通常被成为三阴性乳腺癌,这就意味着这种恶性乳腺癌对于常见的医疗手段并没有任何反应;基底细胞样型乳腺癌更容易发生转移,快速且容

JCO:不同亚型乳腺癌,使用来曲唑效果不同

浸润性小叶癌(ILC)是第二常见的乳腺癌亚型,大约有10%的乳腺癌是这一亚型。ILC在流行病学、临床病理学特征以及对全身性治疗的响应不同于最常见的亚型浸润性导管癌(IDC)。回顾性研究表明早期ILC对于化疗的响应差于IDC。比较ILC和IDC激素疗法的有效性的资料较少。目前仍不清楚不同的疗法对于不同的亚型是不是有差异。为了评估来曲唑用于IDC或ILC相对于他莫西芬的相对效力。研究人员进行了临床试验

Cell Report:阻断氧气传感分子PHD2可抑制乳腺癌的转移

比利时鲁汶大学研究人员发现,降低氧气传感分子PHD2的表达可削弱乳腺癌转移(扩散)到身体其他部位的能力。乳腺癌是女性癌症死亡的第二大死因,主要死于癌细胞的转移。这些表明,抑制PHD2可能在治疗乳腺癌方面具有潜在的价值。该研究成果发表于 Cell Reports。本研究首次检测了自发性乳腺癌模型(相比于以往的移植性肿瘤与人类癌症更相似)中阻断PHD2表达的作用。该研究还发现了基质成纤维细胞(支持并

Baidu
map
Baidu
map
Baidu
map